In our rodent model studies of rheumatoid arthritis, we found that HE3286 treatment benefit was associated with reduced IL-17, TNFα and IL-6 signaling and dramatic reductions in IL-6 and matrix metalloproteinase mRNA in inflamed joint tissue accompanied by an expansion of regulatory T cells in the spleen [51]. This evidence concerns the gene IL17A and rheumatoid arthritis.